ilorasertib: Clinical Trials

4 trials of ilorasertib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3
Phase 21Terminated 1

Follow ilorasertib: new trials by email Literature Review of ilorasertib trials Research Report on ilorasertib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors
Ilorasertib - Advanced Cancers
Phase 2TerminatedM.D. Anderson Cancer Center122016-08-052023-07-17
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
Ilorasertib, Laboratory Biomarker Analysis - Metastatic Malignant Neoplasm, Solid Neoplasm
Phase 1CompletedUniversity of Chicago122015-09-082019-04-22
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
ABT-348, ABT-348 and azacitidine - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Phase 1CompletedAbbVie (prior sponsor, Abbott)522010-04-012017-11-20
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
ABT-348, ABT-348 and carboplatin, ABT-348 and docetaxel - Advanced Solid Tumors
Phase 1CompletedAbbVie (prior sponsor, Abbott)1022010-03-012013-11-06

Conditions studied

Neoplasm Metastasis (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Sponsors

AbbVie (prior sponsor, Abbott) (2)  ·  M.D. Anderson Cancer Center (1)  ·  University of Chicago (1)

Countries

United States (4)

Top investigators

Gary Gordon, MD (2)  ·  David S. Hong, MD (1)  ·  Manish Sharma (1)

Results publications

PMID 25933833, PMID 29551775

NIH funding

P30CA014599 (1)